Manorama Industries has issued a postal ballot notice seeking shareholder approval to appoint Dr. Rohini Tiwari as a non-executive independent director. The Board of Directors approved the appointment on September 4, 2026, following recommendations from the Nomination and Remuneration Committee.

The proposed term spans five consecutive years, commencing on September 4, 2026, and ending on September 3, 2031. Dr. Tiwari was initially appointed as an additional director in this capacity on September 4, 2026, pursuant to Section 161 of the Companies Act, 2013.

Voting Process

Shareholders holding equity shares as of the cut-off date of September 11, 2026, are eligible to vote via remote e-voting. The voting window opens at 9:00 am on Saturday, September 19, 2026, and closes at 5:00 pm on Sunday, October 18, 2026. The company has engaged MUFG Intime India Private Limited to facilitate the electronic voting process.

M/s. Mehta & Mehta has been appointed as the scrutinizer to oversee the postal ballot process. Ms. Alifya Sapatwala will represent the firm, with Ms. Namrata Tatiya serving as alternate representative.

Director Profile

Dr. Rohini Tiwari brings multidisciplinary experience in food technology, nutrition, and quality assurance. She holds a Ph.D. in Food Science and Nutrition and has served as Chief Clinical Nutritionist at Ganga Hospital, Coimbatore. Her industry background includes quality assurance roles at Hindustan Coca-Cola Beverages Pvt. Ltd. and nutraceutical R&D consultancy with Dr. Reddy's Laboratories.

The appointment is subject to member approval via special resolution. The results will be declared on or before October 20, 2026, after the scrutinizer submits its report.

Manorama Industries Limited approved a total share capital increase of up to ₹70 crore across six wholly-owned subsidiaries during its board meeting on September 4, 2026. The infusions target operations in Ghana, Nigeria, Burkina Faso, Chad, Brazil, and the UAE to meet working capital requirements.

The company also appointed Dr. Rohini Tiwari as an additional non-executive independent director for a five-year term starting September 4, 2026. The board noted the completion of Mr. Mudit Kumar Singh’s tenure as an independent director effective September 5, 2026.

Subsidiary Capital Infusions

The board authorized cash subscriptions to increase the share capital of its international trading subsidiaries. The transactions are structured as related-party deals on an arm’s-length basis.

The funds are intended for working capital and general corporate purposes. The company plans to deploy capital in a phased manner aligned with business milestones.

What the Numbers Show

The capital allocation highlights a divergence between established revenue generators and new market entries. While Manorama Savanna Ghana Limited recorded a turnover of approximately ₹160 crore in FY25-26, four of the six subsidiaries received significant capital injections despite reporting nil turnover. This suggests the ₹70 crore outlay is primarily focused on scaling infrastructure in newer jurisdictions like Chad, Burkina Faso, and the UAE rather than just supporting existing high-volume operations.

Governance Updates

Dr. Rohini Tiwari brings expertise in food science, nutrition, and quality assurance from her previous roles at Hindustan Coca-Cola Beverages Pvt. Ltd., Ganga Hospital, and Dr. Reddy’s Laboratories. She will serve until September 3, 2031, subject to member approval via postal ballot.

The postal ballot notice will be sent electronically to members registered as on September 11, 2026. M/s Mehta & Mehta were appointed as scrutinizers, and MUFG Intime India Private Limited will provide the e-voting platform.